ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Enliven Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$38.70+1.38 (+3.70%)
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
80M of 73M shares
Institutional holders
211
63 new, 18 sold out
Net institutional buying
17M
In Q2 2026
Insider trades, 12 months
0 buys · 73 sales
Net sold $75.83M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC | 6,774,507 | 9.50% | 13D (active) amendment | Jun 22, 2026 |
| Robert Egen Atkinson | 6,022,957 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Polar Capital LLP | 59,800,406 | 8.47% | 13G (passive) amendment | Mar 31, 2026 |
| Polar Capital Funds PLC - Biotechnology Fund | 5,056,807 | 8.46% | 13G (passive) amendment | Mar 31, 2026 |
| Commodore Capital LP | 4,800,940 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
| Tomas Kiselak | 3,711,444 | 6.30% | 13G (passive) amendment | Jun 30, 2025 |
| Vestal Point Capital, LP | 3,250,000 | 5.40% | 13G (passive) amendment | Mar 31, 2026 |
| Bong Y. Koh | 3,226,331 | 5.40% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 2,941,395 | 5.10% | 13G (passive) amendment | Jun 30, 2025 |
| Polar Capital Holdings Plc | 2,536,881 | 5.17% | 13G (passive) | Jun 30, 2025 |
| Abigail P. Johnson | 10,713,540 | 15.00% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 10,025,017 | 13.68% | $508.77M | +3,195,771 | 0.02% |
| Orbimed Advisors LLC | 6,776,632 | 9.25% | $343.91M | −1,182,906 | 6.37% |
| Polar Capital Holdings Plc | 6,430,636 | 8.78% | $326.35M | +1,364,703 | 0.77% |
| BlackRock, Inc. | 4,359,704 | 5.95% | $221.25M | +674,997 | 0.00% |
| Vestal Point Capital, LP | 4,000,000 | 5.46% | $203.00M | +750,000 | 4.74% |
| Commodore Capital LP | 3,275,000 | 4.47% | $166.21M | – | 9.90% |
| Price T Rowe Associates Inc /Md/ | 2,903,907 | 3.96% | $147.37K | +2,806,160 | 0.01% |
| Vanguard Capital Management LLC | 2,569,002 | 3.51% | $130.38M | +400,840 | 0.00% |
| Citadel Advisors LLC | 2,068,992 | 2.82% | $105.00M | +325,077 | 0.01% |
| Fairmount Funds Management LLC | 1,855,644 | 2.53% | $94.17M | – | 6.22% |
| Siren, L.L.C. | 1,774,411 | 2.42% | $90.05M | +1,028,185 | 1.82% |
| Bellevue Group AG | 1,490,000 | 2.03% | $75.62M | −830,867 | 1.59% |
| Geode Capital Management, LLC | 1,407,202 | 1.92% | $71.43M | +340,782 | 0.00% |
| First Light Asset Management, LLC | 1,360,750 | 1.86% | $69.06M | +1,158,883 | 4.20% |
| State Street Corp | 1,213,616 | 1.66% | $61.59M | +122,510 | 0.00% |
| Pictet Asset Management Holding SA | 1,161,784 | 1.59% | $58.96M | +232,240 | 0.06% |
| Adage Capital Partners Gp, L.L.C. | 1,083,313 | 1.48% | $54.98M | New | 0.08% |
| Novo Holdings A/S | 1,000,000 | 1.36% | $50.75M | −280,000 | 2.95% |
| First Turn Management, LLC | 954,360 | 1.30% | $48.43M | +330,521 | 5.18% |
| Samlyn Capital, LLC | 912,637 | 1.25% | $46.32M | New | 0.75% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 211 | 80M | 100.0% | 63 / 87 | 48 / 18 | 25M | 7M |
| Q1 2026 | 170 | 63M | 86.2% | 64 / 63 | 32 / 19 | 18M | 14M |
| Q4 2025 | 126 | 62M | 85.2% | 20 / 46 | 45 / 26 | 8M | 5M |
| Q3 2025 | 134 | 59M | 81.1% | 20 / 59 | 32 / 10 | 5M | 5M |
| Q2 2025 | 124 | 60M | 81.2% | 24 / 57 | 23 / 20 | 13M | 3M |
| Q1 2025 | 121 | 50M | 68.1% | 22 / 42 | 35 / 13 | 2M | 2M |
| Q4 2024 | 113 | 50M | 67.7% | 22 / 45 | 25 / 11 | 4M | 3M |
| Q3 2024 | 102 | 48M | 65.1% | 20 / 41 | 23 / 10 | 6M | 4M |
| Q2 2024 | 93 | 49M | 66.8% | 32 / 36 | 15 / 12 | 8M | 4M |
| Q1 2024 | 74 | 45M | 60.9% | 16 / 26 | 21 / 3 | 7M | 2M |
| Q4 2023 | 62 | 39M | 53.4% | 8 / 24 | 12 / 7 | 2M | 2M |
| Q3 2023 | 61 | 39M | 53.3% | 6 / 22 | 22 / 8 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ELVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,883,372 | 2.57% | $95.58M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,250,754 | 1.71% | $68.55M | 0.78% | Jul 31, 2026 |
| Select Health Care Portfolio | 1,120,000 | 1.53% | $44.32M | 0.77% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,117,241 | 1.52% | $56.70M | 0.07% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 807,329 | 1.10% | $40.97M | 0.28% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 670,000 | 0.91% | $36.72M | 1.18% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 648,114 | 0.88% | $35.52M | 0.77% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 647,454 | 0.88% | $32.86M | 0.28% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 624,675 | 0.85% | $31.70M | 0.03% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 579,691 | 0.79% | $31.77M | 0.43% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 501,368 | 0.68% | $27.48M | 1.25% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 468,494 | 0.64% | $25.68M | 0.08% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 468,248 | 0.64% | $23.76M | 0.24% | Jun 30, 2026 |
| Small Cap Growth Fund | 427,901 | 0.58% | $23.45M | 0.42% | Jul 31, 2026 |
| Fidelity U.S. Equity Central Fund | 400,000 | 0.55% | $20.30M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard A. Fair | PRESIDENT AND CEO, Director | – | – | Dec 12, 2025 |
| Samuel Kintz | PRESIDENT AND CEO, Director | 890,392 | 1.22% | Nov 19, 2025 |
| Benjamin Hohl | CHIEF FINANCIAL OFFICER | 38,000 | 0.05% | Sep 21, 2026 |
| Helen Louise Collins | CHIEF MEDICAL OFFICER | 25,000 | 0.03% | Sep 21, 2026 |
| Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | 758,938 | 1.04% | Feb 17, 2026 |
| Anish Patel | CHIEF OPERATING OFFICER | 235,011 | 0.32% | Feb 17, 2026 |
| Mika K. Derynck | Director | 87,373 | 0.12% | Aug 6, 2026 |
| Lori Anne Kunkel | Director | 47,773 | 0.07% | Jul 8, 2026 |
| Richard A. Heyman | Director | 146,320 | 0.20% | Feb 19, 2026 |
| Jake Bauer | Director | 87,372 | 0.12% | Feb 17, 2026 |
| J. Scott Garland | Director | – | – | Feb 17, 2026 |
| Rahul D. Ballal | Director | 22,341 | 0.03% | Feb 17, 2026 |
| Rishi Gupta | Director | 7,663,349 | 10.46% | Feb 17, 2026 |
| Andrew John Phillips | Director | – | – | Feb 10, 2025 |
| Genesis GP LLC OrbiMed | 10% owner | 8,661,225 | 11.82% | Jun 24, 2026 |
| Advisors Llc Orbimed | 10% owner | 219,405 | 0.30% | Jun 24, 2026 |
| Capital GP VII LLC OrbiMed | 10% owner | 7,663,349 | 10.46% | Jun 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −240 | $51.48 | $12.36K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −2,916 | $50.03 | $145.89K | 27,084 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −1,844 | $50.71 | $93.51K | 25,240 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −289 | $51.49 | $14.88K | 38,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −2,194 | $50.72 | $111.28K | 38,289 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −3,535 | $50.03 | $176.86K | 40,483 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Sep 17, 2026 | Option exercise | +3,982 | $14.85 | $59.13K | 44,018 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −1,100 | $59.35 | $65.29K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Aug 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −3,900 | $58.37 | $227.64K | 26,100 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −1,388 | $59.35 | $82.38K | 40,036 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Aug 17, 2026 | Sale(10b5-1 plan) | −4,630 | $58.35 | $270.16K | 41,424 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +87,373 | $2.48 | $216.69K | 87,373 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +27,567 | $25.28 | $696.89K | 114,940 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +23,364 | $14.85 | $346.96K | 138,304 |
| Mika K. Derynck Director | Aug 4, 2026 | Option exercise | +20,491 | $22.47 | $460.43K | 158,795 |
| Mika K. Derynck Director | Aug 4, 2026 | Sale(10b5-1 plan) | −158,795 | $60.21 | $9.56M | 0 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −459 | $51.55 | $23.66K | 29,310 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −231 | $50.05 | $11.56K | 29,769 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −63 | $53.92 | $3.40K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,184 | $53.42 | $116.67K | 25,063 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,063 | $52.39 | $108.08K | 27,247 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,564 | $52.32 | $134.15K | 48,815 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −369 | $51.48 | $19.00K | 51,379 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −324 | $49.97 | $16.19K | 51,748 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Option exercise | +1,072 | $2.48 | $2.66K | 52,072 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −2,638 | $53.38 | $140.82K | 46,177 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jul 17, 2026 | Sale(10b5-1 plan) | −123 | $53.87 | $6.63K | 46,054 |
| Lori Anne Kunkel Director | Jul 6, 2026 | Sale(10b5-1 plan) | −4,111 | $49.98 | $205.47K | 47,773 |
| Lori Anne Kunkel Director | Jul 6, 2026 | Sale(10b5-1 plan) | −5,889 | $50.84 | $299.40K | 41,884 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −1,477 | $45.00 | $66.47K | 219,405 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −787,024 | $45.38 | $35.72M | 6,601,878 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −46,776 | $45.00 | $2.10M | 6,555,102 |
| Advisors Llc Orbimed 10% owner | Jun 22, 2026 | Sale | −24,846 | $45.38 | $1.13M | 220,882 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,133 | $44.74 | $50.69K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −2,599 | $43.87 | $114.02K | 26,133 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,268 | $42.83 | $54.31K | 28,732 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Jun 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,379 | $42.79 | $59.01K | 55,639 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −3,401 | $43.86 | $149.17K | 52,238 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Sale(10b5-1 plan) | −1,238 | $44.75 | $55.40K | 51,000 |
| Benjamin Hohl CHIEF FINANCIAL OFFICER | Jun 17, 2026 | Option exercise | +6,018 | $2.48 | $14.92K | 57,018 |
| Advisors Llc Orbimed 10% owner | Jun 15, 2026 | Sale | −272,322 | $45.02 | $12.26M | 7,388,902 |
| Advisors Llc Orbimed 10% owner | Jun 15, 2026 | Sale | −9,086 | $45.02 | $409.05K | 245,728 |
| Lori Anne Kunkel Director | Jun 5, 2026 | Sale(10b5-1 plan) | −1,867 | $35.36 | $66.02K | 52,238 |
| Lori Anne Kunkel Director | Jun 5, 2026 | Sale(10b5-1 plan) | −7,779 | $34.28 | $266.66K | 54,105 |
| Lori Anne Kunkel Director | Jun 5, 2026 | Sale(10b5-1 plan) | −354 | $35.82 | $12.68K | 51,884 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Sale(10b5-1 plan) | −223 | $41.21 | $9.19K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Sale(10b5-1 plan) | −3,475 | $39.53 | $137.37K | 26,525 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | May 18, 2026 | Sale(10b5-1 plan) | −1,302 | $40.25 | $52.41K | 25,223 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −2,419 | $47.39 | $114.64K | 27,441 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −140 | $45.81 | $6.41K | 29,860 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale(10b5-1 plan) | −2,441 | $48.06 | $117.31K | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Apr 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Mar 25, 2026 | Sale(10b5-1 plan) | −40,000 | $35.10 | $1.40M | 25,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Mar 25, 2026 | Option exercise | +40,000 | $2.48 | $99.20K | 65,000 |
| Helen Louise Collins CHIEF MEDICAL OFFICER | Mar 17, 2026 | Option exercise | +5,000 | $2.48 | $12.40K | 30,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Garland Jeffrey Director | Oct 1, 2026 | 13,000 | $606.72K | Oct 1, 2026 | Stock Option Exercise |
| Benjamin Hohl Officer | Sep 17, 2026 | 12,036 | $591.21K | Sep 17, 2026 | Long shares from previous exercised options |
| Richard A. Heyman resigned from BOD | Sep 4, 2026 | 38,000 | $2.25M | Sep 4, 2026 | Stock Options Exercise |
| Mika K. Derynck Director | Aug 4, 2026 | 158,795 | $9.22M | Aug 4, 2026 | Stock Options |
| Helen Louise Collins Officer | Jul 17, 2026 | 15,000 | $762.90K | Jul 17, 2026 | Stock Options |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Jun 22, 2026 | 26,323 | $1.21M | Jun 22, 2026 | Merger |
| OrbiMed Private Investments VII, LP Shareholder | Jun 22, 2026 | 833,800 | $38.32M | Jun 22, 2026 | Merger |
| Biotech Growth Trust PLC The Shareholder | Jun 22, 2026 | 31,132 | $1.43M | Jun 22, 2026 | Merger |
| Benjamin Hohl Officer | Jun 17, 2026 | 18,054 | $768.20K | Jun 17, 2026 | Stock Option Exercise |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Jun 15, 2026 | 9,086 | $384.88K | Jun 15, 2026 | Merger |
| OrbiMed Private Investments VII, LP Shareholder | Jun 15, 2026 | 272,322 | $11.54M | Jun 15, 2026 | Merger |
| Biotech Growth Trust PLC The Shareholder | Jun 15, 2026 | 10,243 | $433.89K | Jun 15, 2026 | Merger |
| Lori Anne Kunkel Board Member | Jun 5, 2026 | 20,000 | $709.80K | Jun 5, 2026 | Pre-IPO Shares |
| Helen Louise Collins Officer | May 18, 2026 | 15,000 | $620.10K | May 18, 2026 | Stock Options |
| Joseph P. Lyssikatos Officer | Apr 30, 2026 | 25,000 | $1.06M | Apr 30, 2026 | Founder shares |